RenovoRx

RNXT

Market cap $42M

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer

Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System  RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with 19 Issued or Allowed Patents and 14 Pending Patents Supporting the Commercialization of the RenovoCath Device MOUNTAIN VIEW, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More

RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for Drug-Delivery in Oncology Management MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion in the first half of 2026, with final data expected in 2027.

Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones

MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/.

Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device